Filtered By:
Source: Expert Review of Neurotherapeutics
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 10670 results found since Jan 2013.
Transdermal buprenorphine for moderate chronic noncancer pain syndromes.
Authors: Pergolizzi JV, Coluzzi F, Taylor R
Abstract
INTRODUCTION: Chronic noncancer pain has remained a challenging clinical problem. Opioid analgesics are effective, but they are known to be associated with opioid use disorder and potentially treatment-limiting side effects. Buprenorphine is a Schedule III synthetic opioid in the USA with a chemical structure similar to that of morphine but with a longer duration of action, greater potency, and other unique pharmacological attributes. Its role in treatment of chronic noncancer pain may be broader than currently thought. Areas covered: The pharmacokinetics, pharmacod...
Source: Expert Review of Neurotherapeutics - April 19, 2018 Category: Neurology Tags: Expert Rev Neurother Source Type: research
How would defining Parkinson's as a prion disease impact the search of a cure?
Authors: Scialò C, Legname G
PMID: 32253950 [PubMed - as supplied by publisher]
Source: Expert Review of Neurotherapeutics - April 8, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research
An update on acute and preventive treatments for migraine in children and adolescents.
Authors: Rao R, Hershey AD
Abstract
INTRODUCTION: Migraine is diagnosed in 5% of children in the United States by the age of ten. The estimated prevalence for children with migraine is 10%. It has become increasingly important to diagnose children and adolescents with migraine as they are disabling. Children are more likely to miss school and activities due to headaches compared to other children. In addition, poor management and treatment in children and adolescents could potentially lead to an increase in migraine in adults.
AREAS COVERED: A Medline OVID database search was conducted for each acute and preventive...
Source: Expert Review of Neurotherapeutics - July 25, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research
Developing precision treatments for epilepsy using patient and animal models.
Authors: Łukawski K, Czuczwar SJ
Abstract
INTRODUCTION: Phenytoin was the first antiepileptic drug (AED) discovered in an animal model of seizures whose clinical efficacy was subsequently confirmed. This clearly indicated that a search for other AEDs had to consider animal studies.
AREAS COVERED: Main seizure tests used for the evaluation of possible anticonvulsive activity of potential anticonvulsants and their predictive values have been reviewed. Procedures used for the estimation of antiepileptogenic effects have been also included.
EXPERT OPINION: First-line seizure models comprise maximal electroshock (ME...
Source: Expert Review of Neurotherapeutics - December 20, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research
Developing precision treatments for epilepsy using patient and animal models
Expert Rev Neurother. 2020 Dec 29:1-10. doi: 10.1080/14737175.2021.1866989. Online ahead of print.ABSTRACTIntroduction: Phenytoin was the first antiepileptic drug (AED) discovered in an animal model of seizures whose clinical efficacy was subsequently confirmed. This clearly indicated that a search for other AEDs had to consider animal studies. Areas covered: Main seizure tests used for the evaluation of possible anticonvulsive activity of potential anticonvulsants and their predictive values have been reviewed. Procedures used for the estimation of antiepileptogenic effects have been also included. Expert opinion: First-l...
Source: Expert Review of Neurotherapeutics - December 19, 2020 Category: Neurology Authors: Krzysztof Łukawski Stanis ław J Czuczwar Source Type: research
